advertising
-
1
Alexiadou K, Doupis J: Management of diabetic foot ulcers. Diabetes Ther 3: 4, 2012.
-
2
Li Y, Burrows NR, Gregg EW, et al: Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 1988-2008. Diabetes Care 35: 273, 2012.
-
3
Armstrong DG, Wrobel J, Robbins JM: Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 4: 286, 2007.
-
4
International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers . Wounds International. Available at: http://www.woundsinternational.com/pdf/content_10803.pdf. Accessed November 4, 2015.
-
5
Brownrigg JR, Davey J, Holt PJ, et al: The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia 55: 2906, 2012.
-
6
Braun L, Kim PJ, Margolis D, et al: What's new in the literature: an update of new research since the original WHS diabetic foot ulcer guidelines in 2006. Wound Repair Regen 22: 594, 2014.
-
7
Margolis DJ, Kantor J, Berlin JA: Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22: 692, 1999.
-
8
Yosuf MK, Mahadi SI, Mahmoud SM, et al: Diabetic neuropathic forefoot and heel ulcers: management, clinical presentation and outcomes. J Wound Care 24: 420, 2015.
-
9
Yotsu RR, Pham NM, Oe M, et al: Comparison of characteristics and healing course of diabetic foot ulcers by etiological classification: neuropathic, ischemic, and neuro-ischemic type. J Diabetes Complications 28: 528, 2014.
-
10
Schultz GS, Davidson JM, Kirsner RS, et al: Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 19: 134, 2011.
-
11
Snyder DL, Sullivan N, Schoelles KM: Skin Substitutes for Treating Chronic Wounds , Agency for Healthcare Research and Quality, Rockville, MD, 2012.
-
12
Werber B, Martin E: A prospective study of 20 foot and ankle wounds treated with cryopreserved amniotic membrane and fluid allograft. J Foot Ankle Surg 52: 615, 2013.
-
13
Ueta M, Kweon MN, Sano Y, et al: Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction. Clin Exp Immunol 129: 464, 2002.
-
14
Hao Y, Ma DH, Hwang DG, et al: Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 19: 348, 2000.
-
15
Parolini O, Solomon A, Evangelista M, et al: “Human Term Placenta as a Therapeutic Agent: From the First Clinical Applications to Future Perspectives,” in Human Placenta: Structure and Development, Circulation and Functions , edited by E Berven, A Freberg, p 1, Nova Science Publishers Inc, Hauppauge, NY, 2010.
-
16
Lintzeris D, Yarrow K, Johnson L, et al: , 'Case series demonstrating the impact of dehydrated human amniotic membrane allograft on would healing in acute and chronic wounds ' (2014 ) [poster]. Presented at Las Vegas, NV; October 16–18, , Fall 2014 Symposium on Advanced Wound Care. .
-
17
Shah AP: Using amniotic membrane allografts in the treatment of neuropathic foot ulcers. JAPMA 104: 198, 2014.
-
18
Sheikh ES, Sheikh ES, Fetterolf DE: Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J 11: 711, 2014.
-
19
Forbes J, Fetterolf DE: Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care 21: 290, 2012.
-
20
Regulski M, Jacobstein DA, Petranto RD, et al: A retrospective analysis of a human cellular repair matrix for the treatment of chronic wounds. Ostomy Wound Manage 59: 38, 2013.
-
21
Zelen CM, Serena TE, Denoziere G, et al: A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J 10: 502, 2013.
-
22
Zelen CM: An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care 22: 347, 2013.
-
23
Serena TE, Carter MJ, Le LT, et al: A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen 22: 688, 2014.
-
24
Sanders L, Landsman AS, Landsman A, et al: A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage 60: 26, 2014.
-
25
Edmonds M: Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 8: 11, 2009.
-
26
Marston WA, Hanft J, Norwood P, et al: The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26: 1701, 2003.
-
27
Veves A, Falanga V, Armstrong DG, et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24: 290, 2001.
A Retrospective Case Series of a Dehydrated Amniotic Membrane Allograft for Treatment of Unresolved Diabetic Foot Ulcers
Search for other papers by Barry I. Rosenblum in
Current site
Google Scholar
PubMed
Background:
Foot ulcers are among the most serious complications of diabetes and can lead to amputation. Diabetic foot ulcers (DFUs) often fail to heal with standard wound care, thereby making new treatments necessary. This case series describes the addition of a dehydrated amniotic membrane allograft (DAMA) to standard care in unresolved DFUs.
Methods:
This is a single-center retrospective chart review of eight patients who had one to three applications of DAMA to nine DFUs that had failed to resolve despite offloading, other standard care, and adjuvant therapies. Following initial DAMA placement, wound size (length, width, depth) was measured every 1 to 2 weeks until closure. The principal outcome assessed was mean time to wound closure; other outcomes included mean percent reduction from baseline in wound area and volume at weeks 2 to 8.
Results:
All wounds were closed a mean of 9.2 weeks after the first DAMA application (range, 3.0–13.5 weeks). Compared with baseline, wound area and volume, respectively, were reduced by a mean of 48% and 60% at week 2 and by 89% and 91% at week 8. Time to closure was shorter among four patients who had three DAMA applications (mean, 8.3 weeks; range, 4.0–11.0 weeks) than among three patients who had only one application (mean, 12.1 weeks; range, 9.5–13.5 weeks).
Conclusions:
Chronic, unresolved DFUs treated with DAMA rapidly improved and reached closure in an average of 9.2 weeks. These cases suggest that DAMA can facilitate closure of DFUs that have failed to respond to standard treatments.
advertising
